Brief: SK Biopharmaceuticals Q3 Operating Loss 9 Billion Won
Nov 10 (Reuters) - SK Biopharmaceuticals Co Ltd
326030.KS :
* Q3 OPERATING LOSS 9 BILLION WON, UP 81% FROM YEAR EARLIER
Further company coverage: 326030.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on SK Biopharmaceuticals Co
See all newsInsilico Medicine hits 3-week high on SK Biopharmaceuticals tie-up
Signs Joint Rd Partnership Agreement With Insilico Medicine
Brief: Insilico Medicine Cayman TopCo Says Co & SK Biopharmaceuticals Enter AI-Powered RD Collab Worth Up To $2.5 Bln
Brief: SK Life Science Announces FDA Acceptance For Review Of New Drug Application For Cenobamate Oral Suspension
Announces Pharmaceutical Supply Contract